Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...

Eli Lilly has announced a strategic collaboration with UK government departments to address population health challenges, ...

Obesity directly affects kidney health and influences chronic kidney disease (CKD) risk and progression through contributing ...

An estimated 15.5 million U.S adults had a current diagnosis of attention-deficit/hyperactivity disorder (ADHD) in 2023, according to research published in the Oct. 10 issue of the U.S. Centers for ...